Pre-made Ertumaxomab benchmark antibody (Bispecific, anti-CD3E;ERBB2/HER2 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-845

Pre-made Ertumaxomab benchmark antibody (Bispecific, anti-CD3E;ERBB2/HER2 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-845-1mg 1mg Inquiry
GMP-Bios-INN-845-10mg 10mg Inquiry
GMP-Bios-INN-845-100mg 100mg Inquiry
GMP-Bios-INN-845-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Ertumaxomab Biosimilar, Bispecific, Anti-Cd3E;Erbb2 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
INN Name Ertumaxomab
TargetCD3E;ERBB2/HER2
FormatBispecific
Derivation
Species Reactivity
CH1 Isotype
VD LC
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies
Conditions Approved
Conditions Active
Conditions Discontinued
Development TechTriomab® (Trifunctional Ab)